Chronicles of a Biosimilar Production Facility 

Biologic restorative items created through rDNA innovation as recombinant protein-based solutions that have been in clinical use since the mid-1980s as unique biopharmaceuticals have extraordinarily added to the treatment of extreme metabolic and degenerative infections. The late close of the information assurance or licenses for the greater part of them made open doors for the advancement of duplicate adaptations of unique biopharmaceuticals with comparative biologic movement (named biosimilars). Generation of these new items is relied upon to take care of overall demand, advance market rivalry, keep up the impetuses for development, and maintain the human services frameworks.

  • Analysis of the Biosimilar Development Pipeline
  • Physicochemical Biosimilar Comparability Studies
  • Biosuperior Development Strategies

Related Conference of Chronicles of a Biosimilar Production Facility 

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
June 08-09, 2018

8th International Conference and Exhibition on GMP, GCP & Quality Control

Philadelphia, Pennsylvania, USA
June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Chronicles of a Biosimilar Production Facility  Conference Speakers

Recommended Sessions

Related Journals

Are you interested in